Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CPS1 | P31327 | 3/20 | 0.43 |
| ▸ | MAOB | P27338 | 4/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.37 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 8/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20136407 | 1.00 | ALDH1A1 (0.46) | ALDH1A1CPS1MAOBMAOAKMT2A | |
| SCHEMBL20136409 | 1.00 | ALDH1A1 (0.46) | ALDH1A1CPS1MAOBMAOAKMT2A | |
| SCHEMBL18489241 | 0.82 | CPS1 (0.50) | ALDH1A1CPS1KMT2A | |
| SCHEMBL18489238 | 0.82 | CPS1 (0.50) | ALDH1A1CPS1KMT2A | |
| SCHEMBL18502969 | 0.82 | CPS1 (0.50) | ALDH1A1CPS1KMT2A | |
| SCHEMBL30628292 | 0.78 | ALDH1A1 (0.58) | ALDH1A1CPS1MAOBMAOAKMT2A | |
| SCHEMBL17420671 | 0.78 | ALDH1A1 (0.58) | ALDH1A1CPS1MAOBMAOAKMT2A | |
| SCHEMBL18302342 | 0.78 | CPS1 (0.43) | CPS1MAOBMAOAKAT6APARP10 | |
| SCHEMBL20148166 | 0.78 | CPS1 (0.43) | CPS1MAOBMAOAKAT6APARP10 | |
| SCHEMBL18302344 | 0.78 | CPS1 (0.43) | CPS1MAOBMAOAKAT6APARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10370370-B2 | Aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors | AXOVANT SCIENCES GMBH (CH) | 2019-08-06 | — | — | US | disclosed |
| US-20180134696-A1 | Aminobenzisoxazole Compounds as Agonists of Alpha7-Nicotinic Acetylcholine Receptors | FORUM PHARMACEUTICALS, INC. | 2018-05-17 | — | — | US | disclosed |
| US-20180134696-A1 | Aminobenzisoxazole Compounds as Agonists of Alpha7-Nicotinic Acetylcholine Receptors | FORUM PHARMACEUTICALS, INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10370370-B2 | Aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors | CHRNA7, CHRNA5, CHRNA2 | ALDH1A1 2556/4885CPS1 3297/4885MAOB 301/4885 |
| US-20180134696-A1 | Aminobenzisoxazole Compounds as Agonists of Alpha7-Nicotinic Acetylcholine Receptors | CHRNA7, CHRNA5, CHRNA2 | ALDH1A1 2821/4885CPS1 3238/4885MAOB 204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.